Drug Overview
Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease. It is administered intravenously and is dissociated into iron and sucrose once in circulation. The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell.
Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease. It is administered intravenously and is dissociated into iron and sucrose once in circulation. The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell.
Table of Contents
Product ProfilesVenofer: Anemia in chronic kidney disease
List of Figures
Figure 1: Venofer for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of Venofer for anemia in chronic kidney disease
Figure 3: Drug assessment summary of Venofer for anemia in chronic kidney disease
Figure 4: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
List of Tables
Table 1: Venofer drug profile
Table 2: Venofer pivotal trial data in anemia in chronic kidney disease
Table 3: Venofer late-phase trial data in anemia in chronic kidney disease
Table 4: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
